

SPECIAL FEATURES

Highlights of This Issue 2465

CCR Translations

- 2467** Shedding Light on *IDH1* Mutation in Gliomas
Todd C. Hollon and Daniel A. Orringer
See related article, p. 2530

- 2470** *HER2* Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
Federico Cappuzzo and Lorenza Landi
See related article, p. 2594

Reviews

- 2473** Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy
Dayana B. Rivadeneira and Greg M. Delgoffe
- 2482** Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
Thomas M. Ashton, W. Gillies McKenna, Leoni A. Kunz-Schughart, and Geoff S. Higgins

Perspective

- 2491** Leveraging the Success of HIV Drug Development Paradigms for Cancer
Gideon M. Blumenthal, Debra Birnkrant, and Richard Pazdur

CANCER THERAPY: CLINICAL

- 2493** Focal Irradiation and Systemic TGF β Blockade in Metastatic Breast Cancer
Silvia C. Formenti, Percy Lee, Sylvia Adams, Judith D. Goldberg, Xiaochun Li, Mike W. Xie, Josephine A. Ratican, Carol Felix, Lin Hwang, Kym F. Faull, James W. Sayre, Sara Hurvitz, John A. Glaspy, Begoña Comin-Anduix, Sandra Demaria, Dörthe Schae, and William H. McBride

- 2505** Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1

Denis Soulières, Lisa Licitra, Ricard Mesía, Éva Remenár, Shau-Hsuan Li, Andrey Karpenko, Marie Chol, Ying A. Wang, Nadia Solovieff, Laurence Bourdeau, Dalila Sellami, and Sandrine Faivre

PERSONALIZED MEDICINE AND IMAGING

- 2517** ER⁺ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltman, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, and Carlos L. Arteaga

- 2530** Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the *IDH1* Mutation Status
Ortrud Uckermann, Tareq A. Juratli, Roberta Galli, Marina Conde, Ralf Wiedemuth, Dietmar Krex, Kathrin Geiger, Achim Temme, Gabriele Schackert, Edmund Koch, Gerald Steiner, and Matthias Kirsch
See related commentary, p. 2467

- 2539** Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture
Ja Hye Myung, Michael J. Eblan, Joseph M. Caster, Sin-Jung Park, Michael J. Poellmann, Kyle Wang, Kevin A. Tam, Seth M. Miller, Colette Shen, Ronald C. Chen, Tian Zhang, Joel E. Tepper, Bishamjit S. Chera, Andrew Z. Wang, and Seungpyo Hong



Table of Contents

CANCER THERAPY: PRECLINICAL

2548 Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status

Paul Mésange, Anaïs Bouygues, Nathalie Ferrand, Michèle Sabbah, Alexandre E. Escargueil, Ariel Savina, Benoist Chibaudel, Christophe Tournigand, Thierry André, Aimery de Gramont, and Annette K. Larsen

2559 IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma



Erik Ladomersky, Lijie Zhai, Alicia Lenzen, Kristen L. Lauing, Jun Qian, Denise M. Scholtens, Galina Gritsina, Xuebing Sun, Ye Liu, Fenglong Yu, Wenfeng Gong, Yong Liu, Beibei Jiang, Tristin Tang, Ricky Patel, Leonidas C. Plataniias, C. David James, Roger Stupp, Rimas V. Lukas, David C. Binder, and Derek A. Wainwright

2574 Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma

Hiroshi Nakashima, Tran Nguyen, Kazue Kasai, Carmela Passaro, Hirotaka Ito, William F. Goins, Imran Shaikh, Ronald Erdelyi, Reiko Nishihara, Ichiro Nakano, David A. Reardon, Ana C. Anderson, Vijay Kuchroo, and E. Antonio Chiocca

2585 Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model

Ferro Nguyen, Ivan Alferiev, Peng Guan, David T. Guerrero, Venkatadri Kolla, Ganesh S. Moorthy, Michael Chorny, and Garrett M. Brodeur

2594 Targeting *HER2* Aberrations in Non-Small Cell Lung Cancer with Osimertinib



Shengwu Liu, Shuai Li, Josephine Hai, Xiaoen Wang, Ting Chen, Max M. Quinn, Peng Gao, Yanxi Zhang, Hongbin Ji, Darren A.E. Cross, and Kwok-Kin Wong
See related commentary, p. 2470

2605 Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers

Elisabetta Marangoni, Cécile Laurent, Florence Coussy, Rania El-Botty, Sophie Château-Joubert, Jean-Luc Servely, Ludmilla de Plater, Franck Assayag, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Justine Fleury, Sophie Vacher, David Gentien, Audrey Rapinat, Pierre Foidart, Nor Eddine Sounni, Agnès Noel, Anne Vincent-Salomon, Marick Lae, Didier Decaudin, Sergio Roman-Roman, Ivan Bièche, Martine Piccart, and Fabien Reyat

2616 The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis

Michael D. Deel, Katherine K. Slemmons, Ashley R. Hinson, Katia C. Genadry, Breanne A. Burgess, Lisa E.S. Crose, Nina Kuprasertkul, Kristianne M. Oristian, Rex C. Bentley, and Corinne M. Linardic

2631 Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Olivia Campagne, Audrey Delmas, Sylvain Fouliard, Marylore Chenel, Gurunadh R. Chichili, Hua Li, Ralph Alderson, Jean-Michel Scherrmann, and Donald E. Mager

2642 Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth *In Vivo*

Robert A. Fenstermaker, Sheila A. Figel, Jingxin Qiu, Tara A. Barone, Sanam S. Dharma, Evan K. Winograd, Phillip M. Galbo, Laura M. Wiltsie, and Michael J. Ciesielski

2653 B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Sigeki Kato, Osamu Maenishi, Kazuko Sakai, Yasutaka Chiba, Takafumi Okabe, Keita Kudo, Yoshikazu Hasegawa, Hiroyasu Kaneda, Michiko Yamato, Kenji Hirotani, Masaaki Miyazawa, Kazuto Nishio, and Kazuhiko Nakagawa

2665 STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner

Shanshan Sun, Yansheng Wu, Wenyu Guo, Feng Yu, Lingping Kong, Yu Ren, Yu Wang, Xiaofeng Yao, Chao Jing, Chao Zhang, Mingyang Liu, Yuqing Zhang, Minghui Zhao, Zhaoqing Li, Chuanqiang Wu, Yu Qiao, Jingxuan Yang, Xudong Wang, Lun Zhang, Min Li, and Xuan Zhou

BIOLOGY OF HUMAN TUMORS

2678 Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma



David G.P. van IJzendoorn, Stefan Sleijfer, Hans Gelderblom, Ferry A.L.M. Eskens, Geert J.L.H. van Leenders, Karoly Szuhai, and Judith V.M.G. Bovée

Table of Contents

2688 Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma

Joanna Przybyl, Jacob J. Chabon, Lien Spans, Kristen N. Ganjoo, Sujay Vennam, Aaron M. Newman, Erna Forgó, Sushama Varma, Shirley Zhu, Maria Debiec-Rychter, Ash A. Alizadeh, Maximilian Diehn, and Matt van de Rijn

2700 Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells

Xueheng Zhao, Marion G. Brusadelli, Sharon Sauter, Melinda Butsch Kovacic, Wujuan Zhang, Lindsey E. Romick-Rosendale, Paul F. Lambert, Kenneth D.R. Setchell, and Susanne I. Wells




AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a histological section of an excisional biopsy from a patient with pseudomyogenic hemangioendothelioma, where the lesion is localized in the dermis. The patient showed complete and durable remission to treatment with telatinib. The mechanism behind this response was elucidated using an *in vitro* model for pseudomyogenic hemangioendothelioma. For details, see the article by van IJzendoorn and colleagues on page 2678 of this issue.



Clinical Cancer Research

24 (11)

Clin Cancer Res 2018;24:2465-2709.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/24/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/24/11>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.